Eli Lilly welcomes competition for cheap insulin in US
The CEO of Eli Lilly calls it an interesting development that Novo Nordisk plans to sell a new, cheap, fast-acting analog insulin product at the supermarket chain Walmart.
BY RITZAU FINANS, TRANSLATED BY NIELSINE NIELSEN
US Eli Lilly welcomes the new competition from low-cost insulin products from Novo Nordisk.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Vifor Pharma gets new CEO
For subscribers
US dermatology top boss moves to Danish biotech firm
For subscribers
